Anticoagulant selection in venous thrombosis — US labelling

For use by healthcare professionals only — read this first This page offers general orientation, not a prescription. Doses and indications must be checked against the current prescribing information for each product before use: labelling changes over time, and this page is not updated automatically. In the United States the authoritative sources are the FDA-approved prescribing information and DailyMed. Every decision must be individualised to the patient — renal and hepatic function, weight, bleeding risk, pregnancy, cancer, drug interactions and adherence.

Why this page exists separately from the Italian one This is not a translation of the Italian anticoagulant selector. That tool is written against Italian labelling (RCP) and refers to AIFA, the Italian regulatory agency — a framework that does not apply outside Italy. The clinical reasoning is largely shared, but the approved indications differ, most importantly for superficial vein thrombosis (see section 2). The two pages are therefore kept as separate documents rather than as language variants of one another.

Deep vein thrombosis and pulmonary embolism

For DVT and PE the direct oral anticoagulants (DOACs) carry FDA-approved indications and are the usual first choice in patients without contraindications. Typical adult regimens in the current US labelling are summarised below.

Agent	Usual adult regimen (DVT/PE)	US label status
Rivaroxaban	15 mg twice daily with food for 21 days, then 20 mg once daily with food	FDA approved
Apixaban	10 mg twice daily for 7 days, then 5 mg twice daily	FDA approved
Edoxaban	60 mg once daily, after 5–10 days of initial parenteral anticoagulation	FDA approved
Dabigatran	150 mg twice daily, after 5–10 days of initial parenteral anticoagulation	FDA approved
Enoxaparin (LMWH)	Weight-based therapeutic dosing; the parenteral option when a DOAC is unsuitable	FDA approved
Fondaparinux	Weight-based once-daily subcutaneous dosing for acute DVT/PE	FDA approved
Warfarin	Dose adjusted to INR 2.0–3.0, with parenteral overlap until the INR is in range	FDA approved

1.1 · Where a DOAC is not the right choice

Severe renal impairment or dialysis, and significant hepatic impairment with coagulopathy: thresholds differ between agents — check the individual label.
Antiphospholipid syndrome, particularly triple-positive: warfarin is preferred, as DOACs performed worse in this population.
Mechanical heart valves and moderate-to-severe mitral stenosis: DOACs are not indicated.
Pregnancy and breastfeeding: LMWH is the standard, and DOACs are avoided.
Extremes of body weight and known interacting drugs (strong P-gp and CYP3A4 inducers or inhibitors).

1.2 · Isolated distal (calf) DVT

Management is more discretionary than for proximal DVT. Depending on symptoms, risk of extension and bleeding risk, the options range from therapeutic anticoagulation to surveillance ultrasound after roughly two weeks, with treatment if the thrombus extends. This is a clinical judgement, not a labelling question.

Superficial vein thrombosis — the key difference from Italy

No FDA-approved indication for SVT This is the substantive difference between this page and the Italian one. Fondaparinux holds a European indication for superficial vein thrombosis of the legs, granted on the basis of the CALISTO trial. That indication does not exist in the US labelling. Anticoagulation for SVT in the United States is therefore off-label whichever agent is chosen, and the decision rests on clinical judgement and on guideline recommendations rather than on an approved indication.

The clinical reasoning nonetheless remains applicable, and turns on the distance of the thrombus from the deep system:

Scenario	Usual approach	Status in the US
Short segment (< 5 cm), remote from the junction	Symptomatic treatment (NSAIDs, compression) and clinical surveillance; anticoagulation not routine	—
Segment ≥ 5 cm, more than 3 cm from the saphenofemoral or saphenopopliteal junction	Prophylactic-intensity anticoagulation for about 45 days is commonly recommended by guidelines	off-label
Within 3 cm of the junction	Treated as a proximal DVT: full therapeutic anticoagulation	Agent used on its DVT indication on-label

A practical consequence In the last row the distinction matters: an SVT within 3 cm of the junction is managed as a DVT, so the agent is being used on its approved DVT indication. In the middle row the same agent at prophylactic intensity for SVT is not, in the US, covered by an approved indication. Documenting this reasoning in the notes is worthwhile.

Duration of treatment

Duration depends on whether the event was provoked and on the balance between recurrence and bleeding risk, not on the choice of agent:

Provoked by a major transient risk factor (surgery, trauma, prolonged immobilisation): typically 3 months.
Unprovoked: at least 3 months, then reassessment for extended anticoagulation, weighing recurrence risk against bleeding risk and patient preference.
Active cancer: extended anticoagulation while the cancer is active; LMWH and certain DOACs are both established options, with attention to gastrointestinal and genitourinary bleeding risk.
Recurrent unprovoked events: indefinite anticoagulation is usually considered.

For extended treatment beyond the initial period, reduced-dose regimens of some DOACs are labelled for the reduction of recurrence risk. Check the specific product.

Sources and verification

This page reflects long-standing regimens in the US labelling, but it has not been verified against the live prescribing information and is not updated automatically. Before acting on any dose, confirm it at source:

DailyMed — the National Library of Medicine repository of current FDA labelling.
Drugs@FDA — approval history and approved labelling.
Current guidance from professional societies — for example the American College of Chest Physicians (CHEST) antithrombotic therapy guidelines and the American Society of Hematology (ASH) guidelines on venous thromboembolism.

Not a substitute for the label or for clinical judgement Nothing on this page overrides the prescribing information or the responsibility of the prescribing clinician. Where this page and the current label disagree, the label prevails.